

**From:** ratna lingamaneni/cambridge/biogen;nsf;ratna.lingamaneni@biogenidec.com;smtp  
**Sent:** Fri Jul 15 2005 13:59:27 EDT  
**To:** [REDACTED];gilmore  
o'neill/cambridge/biogen@biogenidec; [REDACTED]  
[REDACTED];carmen bozic/cambridge/biogen@biogenidec;minhua  
yang/cambridge/biogen@biogenidec; [REDACTED]  
[REDACTED]  
**CC:** ratna lingamaneni/cambridge/biogen@biogenidec; [REDACTED]  
[REDACTED];cara lansden/cambridge/biogen@biogenidec;  
**Subject:** ACTION NEEDED: BG12 preIND package for MS indication - REVIEW

Hello all,

Please find enclosed a draft pre-IND meeting package for BG12 MS indication for your review. Please provide your comments to me by the EOB on Tuesday, July 19th.

For those of you reviewed the BG12 Psoriasis IND, most of the CMC (taken as it is from the IND) and preclinical (updated with info on the completed and ongoing studies) information for this package is taken from the IND.

Let me know if you have any questions regarding this package.

Thank you

-Ratna

-----  
Ratna Lingamaneni  
Manager, Regulatory Affairs  
Tel: (617) 679 - 2231